Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, +5 more
Metabolism (1997) · n=11
Eleven healthy older men aged 64–76 received a single nightly subcutaneous GHRH(1-29) dose of 2 mg for six weeks. Nocturnal GH release rose and isolated muscle-strength measures improved, but IGF-1, body weight, DEXA body composition, glucose, insulin, and lipids did not change — the trial that established single-nightly dosing as less effective than multiple-daily regimens.
This is the Vittone et al. 1997 paper, published in Metabolism by an investigator group spanning the Johns Hopkins University Department of Medicine, the Geriatric Research Education and Clinical Center at the Baltimore VA, and the National Institute on Aging. The trial is one of the two foundational controlled adult-human dosing studies of GHRH(1-29) — the active 29-amino-acid N-terminal fragment that is sermorelin itself — in healthy non-deficient older adults, and it is the paper most commonly paired with Khorram, Laughlin, and Yen 1997 as the load-bearing adult-evidence base for the molecule.
The design enrolled 11 healthy older men aged 64–76 in a 6-week protocol of a single nightly subcutaneous injection of GHRH(1-29) at 2 mg. Endpoints spanned the nocturnal GH-release profile (provocative-style measurement of GH amplitude and integrated-overnight release), IGF-1 and other axis biomarkers, body composition by dual-energy X-ray absorptiometry, body weight, glucose, insulin, lipids, and a panel of isolated muscle-strength and endurance measures. The headline findings split cleanly across two categories. The acute pharmacodynamic effect was real: nocturnal GH release increased significantly versus baseline on the active treatment, with both mean amplitude and peak amplitude rising in response to the nightly dosing — the pituitary somatotrophs responded to the GHRH-receptor agonism as the mechanism would predict. The downstream and tissue-level outcomes, however, were largely null at six weeks: IGF-1 did not rise significantly, body weight did not change, DEXA-measured lean body mass and fat mass did not change, and the glucose, insulin, and lipid panels did not shift meaningfully. Isolated muscle-strength measures (upright row, shoulder press) showed modest improvements, as did muscle endurance, with the authors framing these effects as plausibly mediated by altered muscle energy metabolism rather than by sustained IGF-1-mediated anabolic remodelling.
The most-cited conclusion of the paper — and the framing it is referenced for in the sermorelin peptide page — is the explicit comparison the authors offer between single-nightly and multiple-daily dosing regimens of GHRH(1-29): single-nightly dosing is "less effective than multiple-daily-dose regimens" at producing sustained GH/IGF-1-mediated effects in this population. The practitioner implication runs both directions: the single-nightly schedule is the most common 503A-compounded sermorelin protocol in 2026 clinical practice, and the controlled-trial evidence base for that schedule's downstream anabolic effects in healthy non-deficient older men is, at six weeks and n=11, essentially what this paper reports — a real GH pulse without a measurable body-composition translation.
The sample is small (n=11) and the duration is short (six weeks) — fit-for-purpose for the GH-release pharmacodynamic question but underpowered for body-composition and functional outcomes that would require multi-month observation windows and larger cohorts. The trial enrolled only men, leaving the sex-asymmetric question raised by the parallel Khorram 1997 trial unaddressed in this design. The 2 mg single-nightly dose is the regimen the paper specifically concludes is suboptimal — practitioner protocols that overlay the molecule on this evidence base would need to use higher frequency or different timing to claim alignment with the authors' "more effective" framing, and those higher-frequency regimens have not been independently characterised in equivalent controlled trials. The isolated muscle-strength improvements are isolated by design (specific lift measurements rather than integrated functional outcomes), the effect sizes are modest, and the mechanism the authors invoke (altered muscle energy metabolism rather than IGF-1-mediated anabolic remodelling) is itself underspecified and not independently validated in subsequent work. The trial cohort is healthy non-deficient older men; generalisability to younger biohacker-use populations, to women, and to the polypharmacy and comorbidity contexts of typical compounding-pharmacy prescribing is not addressed. Together with the Khorram 1997 trial, this paper defines the modest scale of the controlled adult evidence base on which the modern off-label use of sermorelin for body composition, recovery, and longevity-adjacent endpoints rests — the GH-pulse mechanism is biomarker-confirmed, and the downstream tissue translation in healthy non-deficient older adults is modest at best.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.